The effect of indomethacin 25 mg 3 times daily during the first 2 postoperative weeks in preventing heterotopic bone formation after cemented total hip arthroplasty was investigated in a randomized, double-blind and placebo-controlled clinical trial on 57 patients. 16 patients were secondarily excluded, leaving 19 patients in the indomethacin group and 22 patients in the placebo group. Evaluated from the 3-month radiographs, 18/19 indomethacin patients developed either no or only the milder Grade 1 ossification. In contrast, 11/22 placebo patients developed Grade 2 or 3 ossifications. Our observations favor indomethacin prophylaxis for 2 weeks in cemented arthroplasty of the hip.
In order to delineate groups of patients suitable for treatment to prevent heterotopic bone formation (HBF) following total hip replacement, 99 patients were examined to evaluate predisposing factors. One year after surgery, HBF was found in 73% of the patients. A significantly increased frequency of HBF was found among men. There was no correlation between age, severity of osteoarthritis, size of osteophytes, or preoperative hip movement and HBF. Previous ipsilateral hip surgery did not increase the risk of HBF. Although not significant, all patients who developed heterotopic bone after previous ipsi- or contralateral hip surgery showed HBF of the same or even a higher grade after the present replacement.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.